Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAFTADINE vs BEPREVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Bepotastine besilate is a selective histamine H1 receptor antagonist. It inhibits histamine-induced vascular permeability, pruritus, and conjunctival inflammation.
FDA: Prevention of itching associated with allergic conjunctivitis,Off-label: No established off-label uses
FDA: Treatment of ocular itching associated with allergic conjunctivitis
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
1 drop in the affected eye(s) twice daily (approximately every 6-8 hours).
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Plasma elimination half-life is approximately 2-3 hours in healthy adults. In patients with renal impairment, half-life may be prolonged (up to 6-8 hours in severe impairment).
Not extensively metabolized; primarily excreted unchanged in urine. Cytochrome P450 metabolism is minimal.
Minimally metabolized; 80% excreted unchanged in urine.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Bepotastine besilate is primarily excreted via renal elimination. Approximately 75-80% of the administered dose is eliminated unchanged in the urine, with less than 10% recovered in feces. Minor biliary excretion occurs.
Approximately 40% bound to plasma proteins.
Approximately 55% bound to plasma proteins, primarily albumin.
Vd is approximately 1.4 L/kg, indicating distribution beyond plasma into extravascular tissues.
Volume of distribution is approximately 0.8 L/kg, indicating distribution into total body water. This suggests moderate tissue penetration.
Systemic bioavailability after topical ocular administration is low (estimated < 0.5%) due to dilution, local metabolism, and limited corneal penetration.
Ophthalmic: Systemic bioavailability is low (less than 1%) due to local administration and limited absorption. No oral bioavailability data as the drug is not administered systemically.
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for any degree of hepatic impairment.
No dose adjustment required for hepatic impairment.
Children 2 years and older: same as adult dose. Safety and efficacy in children under 2 years not established.
Safety and efficacy in pediatric patients below 2 years of age have not been established. For pediatric patients 2 years and older, same as adult dose: 1 drop twice daily.
No specific dose adjustment needed; use same dose as for younger adults.
No specific dose adjustment required; dosing same as for younger adults.
None
None
Do not inject; for topical ophthalmic use only,Avoid wearing contact lenses if eyes are red,May cause temporary blurred vision after instillation,Use with caution in patients with known hypersensitivity
Not for injection; for topical ophthalmic use only.,Avoid wearing contact lenses if eyes are red.,May cause transient stinging or burning upon instillation.
Hypersensitivity to alcaftadine or any component of the formulation
Hypersensitivity to bepotastine or any component of the formulation.
No specific food interactions reported. As an ophthalmic preparation, systemic absorption is minimal and unlikely to be affected by food.
No known food interactions.
Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alcaftadine should be used during pregnancy only if clearly needed.
No adequate and well-controlled studies in pregnant women. Animal studies revealed no evidence of teratogenicity or fetotoxicity at doses up to 2000 times the human ocular dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus.
It is not known whether alcaftadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alcaftadine is administered to a nursing woman. The M/P ratio has not been established.
Excretion in human milk unknown; caution advised. M/P ratio not available. Consider developmental and health benefits of breastfeeding along with mother's clinical need.
No pharmacokinetic studies have been performed in pregnant women. Based on the available animal data and the low systemic exposure after ocular administration, no dosing adjustment is recommended during pregnancy.
No pharmacokinetic data in pregnancy; no dosage adjustment recommended. Use standard adult dosing.
ALCAFTADINE is a topical ophthalmic antihistamine and mast cell stabilizer used for allergic conjunctivitis. Administer one drop twice daily in each affected eye. Onset of action is within minutes. Contraindicated in patients with hypersensitivity to any component. Use with caution in contact lens wearers; remove lenses before instillation and wait 10 minutes before reinserting. Do not touch dropper tip to any surface to avoid contamination.
Bepotastine besilate (Bepreve) is a topical antihistamine and mast cell stabilizer for ocular allergy. Onset of action is within 3 minutes, duration up to 8 hours. May cause transient stinging. Do not use while wearing contact lenses; insert lenses 10 minutes after instillation.
Do not wear contact lenses if your eyes are red; after the redness subsides, wait at least 10 minutes after instilling the drop before reinserting lenses.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Wait at least 5 minutes between using this drug and other eye drops.,If you miss a dose, use it as soon as you remember; if it is almost time for the next dose, skip the missed dose and resume your regular schedule.,Do not use more than prescribed; overuse may cause eye irritation.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Wash hands before and after use.
Instill one drop into the affected eye(s) twice daily.,Remove contact lenses before use; wait at least 10 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,May cause temporary blurred vision; avoid driving until vision clears.,Report any signs of infection or worsening symptoms to your doctor.
"Dextroamphetamine, a central nervous system stimulant, may reduce the sedative effects of Alcaftadine, an antihistamine used for allergic conjunctivitis, by opposing its central histamine H1 receptor blockade. This pharmacodynamic antagonism can lead to diminished sedation and potentially decreased therapeutic efficacy of Alcaftadine for its intended ocular antiallergic effects. Patients may experience reduced symptom relief and increased ocular discomfort."
"Hydroxyamphetamine may decrease the sedative activities of Alcaftadine."
"Phentermine may decrease the sedative activities of Alcaftadine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAFTADINE vs BEPREVE, answered by our medical review team.
ALCAFTADINE is a Ophthalmic Antihistamine that works by Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.. BEPREVE is a Ophthalmic Antihistamine that works by Bepotastine besilate is a selective histamine H1 receptor antagonist. It inhibits histamine-induced vascular permeability, pruritus, and conjunctival inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAFTADINE and BEPREVE depend on the specific clinical indication. These are both Ophthalmic Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAFTADINE is: 1 drop of 0.25% ophthalmic solution in each affected eye twice daily.. The standard adult dose of BEPREVE is: 1 drop in the affected eye(s) twice daily (approximately every 6-8 hours).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAFTADINE and BEPREVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAFTADINE is classified as Category C. Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate a. BEPREVE is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies revealed no evidence of teratogenicity or fetotoxicity at doses up to 2000 times the human ocular dose. Ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.